Vanda Pharmaceuticals (VNDA) Equity Average (2011 - 2026)

Vanda Pharmaceuticals' Equity Average history runs 16 years deep, the most recent figure standing at $304.0 million for Q1 2026.

• In Q1 2026, Equity Average fell 42.1% year-over-year to $304.0 million; the TTM figure through Mar 2026 stood at $304.0 million (down 42.1% YoY), while the FY2025 annual figure was $432.9 million, down 20.1% from the prior year.
• Equity Average came in at $304.0 million for Q1 2026 at Vanda Pharmaceuticals, down from $396.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $544.5 million in Q1 2024 to a low of $304.0 million in Q1 2026.
• A 5-year average of $504.0 million and a median of $525.0 million in 2025 frame the typical range for Equity Average.
• Across the five-year window, Equity Average grew 9.36% in 2022 and sank 42.1% in 2026, its largest moves.
• Vanda Pharmaceuticals' Equity Average stood at $521.4 million in 2022, then grew by 4.33% to $544.0 million in 2023, then dropped by 0.76% to $539.9 million in 2024, then fell by 26.54% to $396.6 million in 2025, then fell by 23.35% to $304.0 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $304.0 million, $396.6 million, and $476.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison